Prof. Dr. med. Dr. h.c.
Matthias H. Tschöp

Helmholtz Munich and Technis­che Univer­sität München

Matthias Tschöp is the Chief Execu­tive Officer and Scien­tific Direc­tor of Helmholtz Munich, Alexan­der von Humboldt Profes­sor at the Techni­cal Univer­sity of Munich and Adjunct Profes­sor at Yale University.

Follow­ing his discov­ery of the human hunger hormone, ghrelin, Matthias Tschöp unrav­eled funda­men­tal gut-brain signals to discover medicines to safely normal­ize body weight in patients strug­gling with obesity. In close collab­o­ra­tion with the chemist Richard DiMarchi, he discov­ered the dual and triple gut hormone co-agonists. Tirzepatide (Mounjaro®, Zepbound®, Eli Lilly & Co.) is the first repre­sen­ta­tive drug in this class that is FDA-approved.

For his achieve­ments, Matthias Tschöp received the Ernst Scher­ing Prize, the Banting Medal and the Heinrich Wieland Prize among many others. He is a member of the Ameri­can Society for Clini­cal Inves­ti­ga­tion, the Ameri­can Associ­a­tion of Physi­cians, the German National Academy of Sciences (Leopold­ina).

Medicine

Research Fields